Esophageal Cancer: Diagnosis and Staging

2012 ◽  
Keyword(s):  
Esophageal Cancer ◽  
Cancer Diagnosis

An enzyme immunoassay for galactosyltransferase isoenzyme II, and its clinical application to cancer diagnosis

1990 ◽  
Vol 36 (4) ◽  
pp. 598-601 ◽  
Author(s):  
M Uemura ◽  
M Yamasaki ◽  
S Yoshida ◽  
T Uezima ◽  
T Sakaguchi ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Esophageal Cancer ◽  
Enzyme Immunoassay ◽  
Cancer Diagnosis ◽  
Blood Type ◽  
Benign Diseases ◽  
Standard Curve ◽  
Color Development ◽  
Sandwich Type ◽  
Normal Controls

Abstract In this "sandwich"-type enzyme immunoassay of galactosyltransferase isoenzyme II (GT-II), we used the monoclonal antibody MAb 3872 previously established and characterized to be specific for GT-II. Plastic beads coated with MAb 3872 were incubated with serum and buffer, washed, then incubated with MAb 3872 conjugated with horseradish peroxidase and again washed. Peroxidase activity remaining on the beads was measured by color development with o-phenylenediamine. The assay standard curve was linear from 0 to 150 kU/L. Inter- and intra-assay CVs were less than 9% and less than 7%, respectively. Mean GT-II values for 370 normal controls were 6.8 (SD 3.4) kU/L with no significant sex-, smoking-, or blood-type-related differences. We also assayed serum from patients with 11 different cancers or with matched benign diseases. The diagnostic sensitivity of GT-II for liver and esophageal cancer was 0.91 and 0.72, respectively, apparently higher than for carcinoembryonic antigen (CEA) or alpha-fetoprotein. GT-II and CEA concentrations in sera were not correlated. Evidently this assay may be useful as a cancer diagnostic test to supplement existing serological methods.

Cardiac death rates after irradiation for esophageal cancer: An epidemiologic study among esophageal cancer survivors.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 4049-4049 ◽  
Author(s):  
Remco Jurriaan Molenaar ◽  
Tomas Radivoyevitch ◽  
Maarten Hulshof ◽  
Hanneke W.M. Van Laarhoven
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Cancer ◽  
Cancer Survivors ◽  
Cell Carcinoma ◽  
Cancer Diagnosis ◽  
Cardiac Disease ◽  
Cardiac Death ◽  
Radiation Group ◽  
Increased Risk ◽  
Radiation Induced

4049 Background: Esophageal cancer is frequently treated with radiation in addition to surgery and/or chemotherapy. Long-term survivors that received radiation may be at risk for radiation-induced cardiotoxicity. Methods: Esophageal cancer survivors (defined as surviving > 5 yrs after diagnosis) from all 18 Surveillance Epidemiology and End Results (SEER) registries from 1973 to 2013 were queried for irradiation status, cause of death and survival using SEERaBomb, a package for the R statistical programming language. Results: 6,514 esophageal cancer survivors were identified, of whom 2,892 (44%) received no radiation therapy and 3,448 (53%) received external beam radiotherapy. Mean age at the time of esophageal cancer diagnosis was 64.0 yrs in the no radiation group and 63.0 yrs in the radiation group. Median person years of follow up after esophageal cancer diagnosis was 8.6 yrs (interquartile range [IQR]: 7-12) in pts receiving no radiation and 7.9 yrs (6-11) in pts receiving radiation. A total of 590 esophageal cancer survivors died of cardiac disease; 254 received no radiation and 336 did receive radiation. Median time to cardiac death after esophageal cancer diagnosis was 32.2 yrs (IQR: 19-38) in pts that received no radiation and 25.3 years (15-30) in pts that received radiation (log-rank P< 0.001). Compared with unirradiated pts, irradiated pts had an increased risk of dying of cardiac disease (hazard ratio [HR] = 1.47; 95% confidence interval [CI]: 1.2-1.7, Cox regression P< 0.001). The association between radiation and cardiac death was the strongest in esophageal cancer pts diagnosed before 1995 (HR = 1.75; 95% CI: 1.4-2.2, P< 0.001) and in squamous cell carcinoma of the esophagus (HR = 1.9; 95% CI: 1.4-2.6, P< 0.001) but not in adenocarcinoma (HR = 1.04; 95% CI: 0.8-1.4, P= 0.8). Conclusions: 5-year esophageal cancer survivors that were treated with radiotherapy have an increased risk of dying of cardiac disease, compared with unirradiated counterparts. This association was strongest in pts treated before 1995 and in squamous cell carcinoma pts. This may be due to late radiation-induced cardiotoxicity, decreasing with the use of heart-sparing radiation techniques after 1995.

A new complementary approach to endoscopy for esophageal cancer diagnosis.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 42-42
Author(s):  
Gengxi Jiang ◽  
Hongmei Tao ◽  
Xing Tang ◽  
Da Lou ◽  
Yue Lin ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Cancer Diagnosis ◽  
Early Stage ◽  
Area Under The Curve ◽  
Squamous Carcinoma ◽  
Pathological Examination ◽  
Control Group ◽  
Threshold Values ◽  
Blood Samples ◽  
Therapeutic Decision Making

42 Background: For esophageal cancer, no viable non-invasive detection technologies are available today. In earlier investigations, Cancer Differentiation Analysis (CDA) Technology which measures information relating to both protein fragments and cellular signals in blood samples in a single test has showed a significant advantage in esophageal cancer diagnosis. Methods: Blood samples from 105 individuals in EDTA tubes were collected from Shanghai Changhai Hospital, China, between July and December 2014, CDA and endoscopy tests were carried out on all samples before clinically diagnosed. A performance predication model of CDA and endoscopy test results was built using pROC package in R Language for the data of Area Under the Curve (AUC) and CDA threshold values. Further analysis was carried out based on the CDA threshold values. Results: Out of the 105 individuals, samples from 6 individuals diagnosed as esophageal benign diseases were selected as control group. 99 samples from individuals diagnosed as esophageal cancer, of which 3 and 82 cases were adenocarcinoma and squamous carcinoma, 2, 26, 33, 31 and 7 cases were classified as stage 0,I,II, III, IV, respectively. Details of AUC results of endoscopy, and CDA plus endoscopy for each group were given in Table 1 below. Conclusions: Even though the sensitivity of the endoscopy is usually high due to its pathological examination, this investigation showed that CDA technology could further enhance the diagnosis sensitivity of endoscope, especially for early stage of esophageal cancer, and it (CDA) can be an effective complementary tool to clinical diagnosis and operation determination while obtaining the pathological information via endoscopy. In conclusion, CDA technology is of great value in esophageal diagnosis and therapeutic decision-making. [Table: see text]

Esophageal Cancer: Diagnosis and Staging

2010 ◽  
pp. 93-105
Author(s):  
J. Rüdiger Siewert ◽  
Marcus Feith
Keyword(s):  
Esophageal Cancer ◽  
Cancer Diagnosis

scholarly journals Statin use after esophageal cancer diagnosis and survival: A population based cohort study

2017 ◽  
Vol 48 ◽  
pp. 124-130 ◽  
Author(s):  
Chris R. Cardwell ◽  
Andrew D. Spence ◽  
Carmel M. Hughes ◽  
Liam J. Murray
Keyword(s):  
Esophageal Cancer ◽  
Cohort Study ◽  
Cancer Diagnosis ◽  
Population Based ◽  
Statin Use

Esophageal Cancer: Diagnosis and Staging

2009 ◽  
pp. 479-488
Author(s):  
J. Rüdiger Siewert ◽  
Marcus Feith
Keyword(s):  
Esophageal Cancer ◽  
Cancer Diagnosis
Sign in / Sign up

Export Citation Format

Share Document